Discontinued — last reported Q4 '23
Business Segments · Payments for Restructuring
CarelonRx Segment — Payments for Restructuring
Elevance Health CarelonRx Segment — Payments for Restructuring remained flat by 0.0% to $250K in Q4 2023 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryLiquidity
SignalLower is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ4 2023Feb 21, 2024
Rolls up toPayments for Restructuring
How to read this metric
High cash payments indicate the active execution phase of a restructuring plan, impacting short-term liquidity.
Detailed definition
This represents the actual cash outflow from the CarelonRx segment to settle obligations related to restructuring activi...
Peer comparison
Often found in the 'Cash Flow from Operating Activities' section or related restructuring disclosures.
Metric ID:
elv_segment_carelonrx_segment_payments_for_restructuringHistorical Data
2 years
| FY'22 | FY'23 | |
|---|---|---|
| Value | $0 | $1M |
Range$0 – $1M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Elevance Health's carelonrx segment — payments for restructuring?
- Elevance Health (ELV) reported carelonrx segment — payments for restructuring of $250K in Q4 2023.
- What does carelonrx segment — payments for restructuring mean?
- The actual cash spent to execute organizational changes in the pharmacy services business.